Henri Knafo

Medical Director, R&D, PDT Global Medical Affairs
Takeda Development Center Americas, Inc., Cambridge, MA, USA
Cambridge, Massachusetts, United States

Presentation(s):

• PB1061 - A phase 3 trial of TAK-330 (4-factor prothrombin complex concentrate [4F-PCC]) vs standard-of-care 4F-PCCs for FXa inhibitor-induced anticoagulation reversal before urgent surgery/invasive procedure

  Tuesday, June 25, 2024
  13:45 – 14:45 ICT